Recursion Pharmaceuticals (RXRX) to Release Quarterly Earnings on Wednesday

Recursion Pharmaceuticals (NASDAQ:RXRX) is expected to be announcing its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $19.36 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 8:00 AM ET.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The business had revenue of $19.10 million during the quarter, compared to analyst estimates of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The business’s revenue for the quarter was up 33.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.40) EPS. On average, analysts expect Recursion Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Recursion Pharmaceuticals Stock Performance

RXRX opened at $5.91 on Wednesday. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02. The firm has a market cap of $2.57 billion, a PE ratio of -3.32 and a beta of 0.91. The business has a fifty day simple moving average of $5.21 and a 200-day simple moving average of $5.21. Recursion Pharmaceuticals has a fifty-two week low of $3.79 and a fifty-two week high of $12.36.

Wall Street Analysts Forecast Growth

RXRX has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Wednesday, October 8th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, September 11th. Finally, Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 target price on the stock. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $7.25.

Insider Buying and Selling at Recursion Pharmaceuticals

In related news, insider Najat Khan sold 36,599 shares of Recursion Pharmaceuticals stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.52, for a total value of $202,026.48. Following the completion of the sale, the insider owned 668,197 shares of the company’s stock, valued at approximately $3,688,447.44. The trade was a 5.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.43% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of RXRX. Hudson Bay Capital Management LP raised its stake in Recursion Pharmaceuticals by 18.0% during the 2nd quarter. Hudson Bay Capital Management LP now owns 150,000 shares of the company’s stock valued at $759,000 after purchasing an additional 22,930 shares during the last quarter. Headlands Technologies LLC increased its holdings in Recursion Pharmaceuticals by 20.2% in the 2nd quarter. Headlands Technologies LLC now owns 199,415 shares of the company’s stock valued at $1,009,000 after buying an additional 33,565 shares during the period. Sender Co & Partners Inc. acquired a new position in shares of Recursion Pharmaceuticals in the 2nd quarter valued at $121,000. HRT Financial LP acquired a new position in shares of Recursion Pharmaceuticals in the 2nd quarter valued at $2,753,000. Finally, Engineers Gate Manager LP bought a new position in shares of Recursion Pharmaceuticals during the 2nd quarter worth about $478,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.